Verano Holdings Corp. (VRNOF)
(Delayed Data from OTC)
$3.62 USD
-0.28 (-7.18%)
Updated Aug 2, 2024 03:59 PM ET
4-Sell of 5 4
B Value B Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Verano Holdings Corp. [VRNOF]
Reports for Purchase
Showing records 101 - 120 ( 145 total )
Company: Verano Holdings Corp.
Industry: Medical - Products
Cannabis on the Ballot for Next Week''s US Midterms
Provider: VENTUM CAPITAL MARKETS
Analyst: Research Department
Company: Verano Holdings Corp.
Industry: Medical - Products
Pick & Roll: Debt Refinancing for Solidity Plus Optionality on $270M to Drive Growth
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Verano Holdings Corp.
Industry: Medical - Products
Refinances $350M Facility, Adds Optionality & Flexibility Out to ''26
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Company: Verano Holdings Corp.
Industry: Medical - Products
3Q22 Preview, NJ & FL Growth Offsetting Industry Softness, PT to $16
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Cannabis 3Q22 Preview: Tempered Growth Ahead of U.S. Federal Catalyst
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly ReHash: Regulatory Steps to Normalize Cannabis, Explicit Safe Harbor Key
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly ReHash: Regulatory Steps to Normalize Cannabis, Explicit Safe Harbor Key
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly Rehash: Cannabis Equity Returns in a Historical Context
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
With Goodness Gone, Verano Will Have More Dry Powder but Fewer Organic Growth Opportunities in 2023, Neutral on Announcement
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Verano Holdings Corp.
Industry: Medical - Products
FCF Step Up on the Horizon as Investments in Adult-Use Capacity Nearly Complete, Goodness Growth to Steepen Growth Trajectory, Q422 Top Pick
Provider: Echelon Welath Partners
Analyst: Research Department
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly ReHash: Canada Update, Sales & Pricing Stabilizing
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly ReHash: Cannabis Sector Performance Analysis
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
We are initiating coverage on Verano Holdings Inc. with a C$22.00 price target.
Provider: VENTUM CAPITAL MARKETS
Analyst: ZANDBERG J
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly ReHash: Start Spreading the Licenses New York, New York
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Weekly ReHash: Assessing 2Q22 Cannabis Earnings
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Verano Holdings Corp.
Industry: Medical - Products
Mixed Q222 as NJ Bump Met with SG&A Jump, Verano Leads Q2 Sales Growth Across Closest Peer Group, Operating Leverage Ahead
Provider: Echelon Welath Partners
Analyst: SEMPLE A